Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

AKYNZEO DIN 02468735

Status: Marketed
Holder: KNIGHT THERAPEUTICS INC.
Molecule: PALONOSETRON (PALONOSETRON HYDROCHLORIDE)
Available to quote

Health Canada record

Active ingredient(s)PALONOSETRON (PALONOSETRON HYDROCHLORIDE) 0.5 MG; NETUPITANT 300 MG
Dosage formCapsule
RouteOral
SchedulePRESCRIPTION
ClassHuman
ATCA04AA55 PALONOSETRON, COMBINATIONS
Original market date20-Nov-2017
Current status date30-Nov-2022
SourceHealth Canada DPD

Establishment licence of the holder

Knight Therapeutics Inc. — licence 3-002350, currently licensed, last inspection rating C (2025-11-05).

No Canadian shortage report is currently matched to this DIN.

Other Canadian products containing PALONOSETRON (PALONOSETRON HYDROCHLORIDE)

DINProductCompanyFormStrengthStatus
02381710ALOXIKNIGHT THERAPEUTICS INC.SolutionPALONOSETRON (PALONOSETRON HYDROCHLORIDE) 0.25 MGMarketed
02381729ALOXIKNIGHT THERAPEUTICS INC.CapsulePALONOSETRON (PALONOSETRON HYDROCHLORIDE) 0.5 MGDormant

Notices of Compliance

NOCDateSubmissionReason
294952022-11-16New Drug Submission (NDS)Administrative: Change in Product Ownership
241802020-09-04New Drug Submission (NDS)CHANAGE IN PROUCT OWNERSHIP
198602017-09-28New Drug Submission (NDS)
Request a quote for AKYNZEO

How to read a Canadian DIN record